Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart radiation aims to zap liver tumors with fewer side effects

NCT ID NCT05027711

Disease control Sponsor: University Hospital Heidelberg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of radiation therapy for people with up to 3 small liver tumors that have spread from another cancer. One method uses standard planning, while the other uses daily MRI scans to adjust the radiation beam in real time. The goal is to see if the MRI-guided approach causes fewer serious side effects while still controlling the tumors. About 90 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy (MR-guided adaptive SBRT or standard ITV-based SBRT)
What this could lead to
If successful, this could show that MR-guided adaptive radiotherapy reduces side effects and improves tumor control for people with liver metastases.
What could go wrong
This is a phase 2 trial with only 90 participants, so results may not apply to everyone. The new technique is more complex and may not always be better than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * confirmed underlying solid malignant tumor (no germ cell tumor, leukemia, lymphoma) * 1-3 hepatic metastases confirmed by pre-therapeutic MRI * indication for SBRT of 1-3 hepatic metastases * maximum diameter each hepatic metastasis ≤ 5 cm (in case of 3 metastases: sum of diameters ≤ 12 cm) * age ≥ 18 years of age * Karnofsky Performance Score ≥ 60% * ability to lie still on the radiotherapy treatment couch for at least one hour * ability to hold one's breath for more than 25 seconds * for women with childbearing potential, adequate contraception * ability of subject to understand character and individual consequences of the clinical trial * written informed consent (must be available before enrolment in the trial) Exclusion Criteria: * refusal of the patients to take part in the study * patients with primary liver cancer (eg. HCC, CCC) * patients after liver transplantation * impairment of liver function to an extent contraindicating radiotherapy (to the discretion of the treating radiation oncologist) * active acute hepatic/biliary infection (e.g. hepatitis, cholangitis, cholecystitis) * previous radiotherapy of the hepatobiliary system, if previous and current target volumes overlap MAESTRO Study Studienprotokoll Seite 25 von 54 Version 1.0 vom 17.12.2020 * patients who have not yet recovered from acute toxicities of prior therapies * claustrophobia * pregnant or lactating women * contraindications against performing contrast-enhanced MRI scans (pacemakers, other implants making MRI impossible, allergy to gadolinium (GD)-based contrast agent) * participation in another competing clinical study or observation period of competing trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic metastasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic metastasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital of Heidelberg, Radiation Oncology

    RECRUITING

    Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.